Latest action: Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill to oversee and hold pharmaceutical companies accountable for investments and spending.
The problem
Pharmaceutical companies make large investments with limited public oversight. Concerns exist about drug pricing, research spending transparency, and accountability to taxpayers.
The proposal
Creates oversight mechanisms for pharmaceutical investment decisions and spending. Requires companies to report on research, development, and marketing expenditures.
The impact
Pharmaceutical companies face new reporting requirements. Patients, taxpayers, and healthcare systems may see changes in drug pricing and availability.
Companies would disclose how they spend money on drugs. This helps patients and doctors understand drug costs better.
Oversight holds companies responsible for their decisions. Public scrutiny may encourage fair pricing and genuine research investment.
Government funding for drug research can be tracked and verified. Money goes where promised instead of being redirected.
Companies spend money reporting and tracking data. These costs may be passed to consumers through higher drug prices.
New rules slow down decision-making and require new staff. Small pharmaceutical companies struggle more with compliance than large ones.
Heavy oversight may discourage companies from investing in new drugs. Innovation could slow if rules are too strict.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.